MAP2K3 is a strong promoter of tumor invasion, progression and short survival in several human cancers [30] and previous studies have shown that decreased expression of MAP2K3 is associated with human breast infiltrating ductal carcinomas [31]; similarly, non-synonymous coding SNPs downregulating KCNJ12 expression have been related with rhabdomyosarcomas [32], supporting a potential role for both genes in liver metastatic sCRC. Here, MAP2K3 is linked to cancer.